Clinical Effect of Carrilizumab Combined with Standard Chemotherapy in First-line Treatment of Inoperable Esophageal Squamous Cell Carcinoma
Objective:To investigate the clinical effect of carrilizumab combined with standard chemotherapy in the first-line treatment of inoperable esophageal squamous cell carcinoma.Method:100 patients with esophageal squamous cell carcinoma who received treatment in the hospital from June 2022 to June 2023 were selected as the study objects and divided into two groups according to random number table method,with 50 cases in each group.Patients in the standard group were treated with cisplatin combined with paclitaxel,and patients in the combined group were treated with carrilizumab on the basis of the standard group.The clinical efficacy,laboratory indicators(CEA,VEGF,SCC-Ag),immune function related indicators(CD3+,CD4+,CD4+/CD8+)and adverse reactions were compared between the two groups.Result:The disease control rate of combined group was 75.56%,higher than 55.56%of standard group,(P<0.05).After treatment,the laboratory indexes of 2 groups were lower than those before treatment,and the combined group was lower than the standard group,(P<0.05).After treatment,the related indexes of immune function in 2 groups were higher than those before treatment,and the combined group was higher than the standard group,(P<0.05).There was no significant difference in adverse reactions between the two groups.Conclusion:Carrellizumab combined with standard chemotherapy in first-line treatment of inoperable esophageal squamous cell carcinoma can effectively reduce the levels of serum CEA,VEGF and SCC-Ag,improve the immune level of patients,and enhance the anti-tumor effect without increasing adverse reactions.
国家科技期刊平台
NSTL
万方数据
